newsfilter
← Latest News
Business Wire·

Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial

Company Executives Available to Meet with Investment Professionals January 8-10 in San Francisco Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company"), a clinical-stage, fully-integrated biotherapeutics